- Advertise
- About OncLive
- Editorial Board
- CancerNetwork.com
- CGTlive.com
- CureToday.com
- OncNursingNews.com
- TargetedOnc.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Rugo on Challenges Faced as a Woman in Oncology
March 11th 2024, 10:12pm
PER® Miami Breast Cancer Conference
Hope S. Rugo, MD, discusses challenges that women face in the workplace in oncology care.
Targeted Delivery of IL-12 Shows Preliminary Antitumor Activity in Advanced Solid Tumors
March 11th 2024, 7:22pm
ESMO Targeted Anticancer Therapies Congress
A high proportion of patients with metastatic solid tumors experienced stable disease following treatment with the immunocytokine in the DODEKA trial.
Dr Shore on Key Clinical Trial Data in Biochemically Recurrent Prostate Cancer
March 11th 2024, 12:39am
US Prostate Cancer Conference (USPCC)
Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.
Dr Hussain on Key Ongoing Clinical Trials in Metastatic Castrate-Resistant Prostate Cancer
March 11th 2024, 12:14am
US Prostate Cancer Conference (USPCC)
Maha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.
MRD Testing Presents Challenges and Opportunities in Breast Cancer Care
March 10th 2024, 7:25pm
PER® Miami Breast Cancer Conference
Heather McArthur, MD, MPH, discusses the prognostic benefits of circulating tumor DNA and limitations that prevent these results from being predictive.
Dr Tripathy on the Management of Early-Stage HER2+ Breast Cancer
March 10th 2024, 3:41pm
Debu Tripathy, MD, discusses current considerations for the management of early-stage HER2-positive breast cancer.
Dr Bochner on Key Points for Community Oncologists in the Management of Muscle-Invasive Bladder Cancer
March 10th 2024, 1:19am
Bernard H. Bochner, MD, FACS, discusses considerations for community oncologists when treating patients with muscle-invasive bladder cancer.
Dr Xu on Treatment Sequencing Considerations in Metastatic Renal Cell Carcinoma
March 10th 2024, 1:14am
Wenxin (Vincent) Xu, MD, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma.
Dr Rugo on the Evolution of ADCs in HR+/HER2+ and HER2-Low Breast Cancer
March 9th 2024, 11:47pm
Hope Rugo, MD, discusses the evolution of antibody-drug conjugates in hormone receptor–positive, HER2-positive, and HER2-low breast cancer.
Artificial Intelligence in Prostate Cancer Pathology: Friend or Foe?
March 9th 2024, 9:41pm
Peter A. Humphrey, MD, PhD, presents on the standing of artificial intelligence in prostate cancer pathology.
Targeted Agents Expand the HR+/HER2– Metastatic Breast Cancer Treatment Arena
March 9th 2024, 8:04pm
Erica Stringer-Reasor, MD, highlights the evolution of therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Dr Huppert on Data Informing the Sequence of Systemic Therapy in Early-Stage TNBC
March 9th 2024, 3:29pm
PER® Miami Breast Cancer Conference
Laura A. Huppert, MD, discusses data informing the sequence of immunotherapy and chemotherapy regimens in early-stage triple-negative breast cancer.
Piecing the Puzzle Together: Treatment After Progression in Metastatic Castration-Resistant Prostate Cancer
March 9th 2024, 2:52pm
The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution.
Dr Tagawa on the Role of PARP Inhibitors in Prostate Cancer Treatment
March 9th 2024, 1:56am
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the standing of PARP inhibitors in the treatment paradigm of metastatic castration-resistant prostate cancer.
Dr Dreicer on Improving Clinical Trial Design in Prostate Cancer
March 9th 2024, 1:41am
Robert Dreicer, MD, discusses the shortcomings of current clinical trials in prostate cancer and what he sees as the biggest area of improvement.
Neoadjuvant Chemotherapy Has Led to De-Escalation of Breast Cancer Surgery and Radiation
March 8th 2024, 11:13pm
PER® Miami Breast Cancer Conference
Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.
PRMT5 Inhibitors Plus Antiestrogens May Combat Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer
March 8th 2024, 11:03pm
PER® Miami Breast Cancer Conference
PRMT5 inhibitors with antiestrogens represents a therapeutic strategy that may overcome resistance to CDK4/6 inhibitors in ER+/RB-deficient breast cancer.
ADCs Serve as “Exciting and Effective Drug Delivery System” in HR+/HER2– Breast Cancer
March 8th 2024, 10:42pm
PER® Miami Breast Cancer Conference
Hope S. Rugo, MD, FASCO, shares progress made with ADCs and the interest in moving these agents up in the HR-positive/HER2-negative breast cancer paradigm.
Racial Disparities Magnified in Cardiac Dose, Toxicity Differences With RT for Breast Cancer
March 8th 2024, 10:18pm
PER® Miami Breast Cancer Conference
Racial and ethnic disparities for mortality are present in breast cancer, especially as it relates to radiation therapy toxicity and cardiac dose.
Dr Litton on Navigating the Sequencing of PARP Inhibitors in Early-Stage TNBC
March 8th 2024, 8:52pm
PER® Miami Breast Cancer Conference
Jennifer K. Litton, MD, discusses challenges determining the optimal sequencing of PARP inhibitors in early-stage triple-negative breast cancer.